EA002819B1 - Циклическое пептидное соединение и его применение, бициклопептидное соединение, пептидное соединение и его применение, фармацевтическая композиция - Google Patents

Циклическое пептидное соединение и его применение, бициклопептидное соединение, пептидное соединение и его применение, фармацевтическая композиция Download PDF

Info

Publication number
EA002819B1
EA002819B1 EA199901025A EA199901025A EA002819B1 EA 002819 B1 EA002819 B1 EA 002819B1 EA 199901025 A EA199901025 A EA 199901025A EA 199901025 A EA199901025 A EA 199901025A EA 002819 B1 EA002819 B1 EA 002819B1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino acid
cyclo
acre
peptide
equivalent amino
Prior art date
Application number
EA199901025A
Other languages
English (en)
Russian (ru)
Other versions
EA199901025A1 (ru
Inventor
Стефен М. Кондон
Изабелль Мориз
Original Assignee
Авентис Фармасьютикалз Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фармасьютикалз Продактс Инк. filed Critical Авентис Фармасьютикалз Продактс Инк.
Publication of EA199901025A1 publication Critical patent/EA199901025A1/ru
Publication of EA002819B1 publication Critical patent/EA002819B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/635Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA199901025A 1997-05-14 1998-05-13 Циклическое пептидное соединение и его применение, бициклопептидное соединение, пептидное соединение и его применение, фармацевтическая композиция EA002819B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4647297P 1997-05-14 1997-05-14
PCT/US1998/009843 WO1998051324A1 (en) 1997-05-14 1998-05-13 Peptide parathyroid hormone analogs

Publications (2)

Publication Number Publication Date
EA199901025A1 EA199901025A1 (ru) 2000-06-26
EA002819B1 true EA002819B1 (ru) 2002-10-31

Family

ID=21943653

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199901025A EA002819B1 (ru) 1997-05-14 1998-05-13 Циклическое пептидное соединение и его применение, бициклопептидное соединение, пептидное соединение и его применение, фармацевтическая композиция

Country Status (20)

Country Link
US (2) US6472505B1 (https=)
EP (1) EP0986395A4 (https=)
JP (1) JP2001517957A (https=)
KR (1) KR100351213B1 (https=)
CN (1) CN1261281A (https=)
AP (1) AP9901686A0 (https=)
AU (1) AU746461B2 (https=)
BG (1) BG103957A (https=)
BR (1) BR9808786A (https=)
CA (1) CA2290443A1 (https=)
EA (1) EA002819B1 (https=)
HU (1) HUP0003349A3 (https=)
IL (1) IL132901A0 (https=)
NO (1) NO995568L (https=)
OA (1) OA11216A (https=)
PL (1) PL336803A1 (https=)
SK (1) SK151599A3 (https=)
UA (1) UA62967C2 (https=)
WO (1) WO1998051324A1 (https=)
ZA (1) ZA984077B (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0101629A2 (en) 1998-04-15 2003-03-28 Aventis Pharma Inc Process for the preparation of resin-bound cyclic peptides
US6316410B1 (en) * 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2003097690A2 (en) * 2002-05-16 2003-11-27 Theratechnologies Inc. Pth derivatives resistant to skin proteases
WO2004073587A2 (en) * 2003-02-19 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with parathyroid hormone receptor 1 (pthr1)
CA2529777A1 (en) * 2003-07-15 2005-01-27 National Research Council Of Canada Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells
US7439226B2 (en) * 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
MXPA06012980A (es) * 2004-05-10 2007-06-12 Nastech Pharm Co Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
WO2007007325A2 (en) 2005-07-07 2007-01-18 Fulcrum Sp Ltd. Sp1 polypeptides, modified sp1 polypeptides and uses thereof
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
AU2007313001B2 (en) * 2006-10-13 2012-03-22 Eli Lilly And Company Pegylated PTH as PTH receptor modulators and uses thereof
US8691760B2 (en) 2009-02-02 2014-04-08 Ramot At Tel-Aviv University Peptides, pharmaceutical compositions comprising same and uses thereof
US8912142B2 (en) 2009-04-01 2014-12-16 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Method of regulating proliferation and differentiation of keratinocyes
WO2010116375A1 (en) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Isolated peptides for regulating apoptosis
US20120070449A1 (en) 2009-05-28 2012-03-22 Yeda Research And Development Co. Ltd. Methods of treating inflammation
ES2729051T3 (es) * 2009-07-29 2019-10-30 Kai Pharmaceuticals Inc Agentes terapéuticos para reducir los niveles de hormona paratiroidea
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9352000B2 (en) 2010-05-05 2016-05-31 Rappaport Family Institute For Research In The Medical Sciences Use of CCL1 in therapy
WO2011143406A2 (en) * 2010-05-13 2011-11-17 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
WO2012017439A2 (en) 2010-08-04 2012-02-09 Ramot At Tel-Aviv University Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
ES2702487T3 (es) * 2011-06-17 2019-03-01 Nantenergy Inc Líquido iónico que contiene iones sulfonato
JP6429191B2 (ja) 2012-03-06 2018-11-28 セレクト バイオセラピューティクス リミテッド アポトーシスシグナル伝達抵抗性細胞を選択する装置および方法ならびにその使用
US9695402B2 (en) 2013-09-17 2017-07-04 Yeda Research And Development Co. Ltd. ERK-derived peptides and uses thereof
WO2015114633A1 (en) 2014-01-30 2015-08-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
US20170174764A1 (en) 2014-03-27 2017-06-22 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
CN113713090B (zh) 2015-02-09 2023-06-02 安特拉贝欧有限公司 骨质疏松症的治疗
EP3261582B1 (en) 2015-02-26 2021-01-06 Remodeless CV Ltd. Methods and compositions relating to leptin antagonists
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
WO2017122209A2 (en) 2016-01-12 2017-07-20 Yeda Research And Development Co. Ltd. NF-kappaB INHIBITORS
IL243839B (en) 2016-01-28 2018-01-31 Sp Nano Ltd Conductive wires
IL243838A (en) 2016-01-28 2017-07-31 Sp Nano Ltd The composition containing sp1 protein and carbon nanoparticles and its uses
EP3464322B1 (en) 2016-06-05 2023-04-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Novel molecules for the treatment of inflammation
WO2018037416A1 (en) 2016-08-25 2018-03-01 Yeda Research And Development Co. Ltd. Methods and compositions for treating autoimmune diseases
SG11201810936VA (en) 2016-12-01 2019-01-30 Univ Ramot Combined treatment for nerve injuries
EP3606615B1 (en) 2017-04-07 2026-01-07 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Method of straightening hair, method for maintenance of straightened hair and kit for straightening hair
US20200172604A1 (en) 2017-05-23 2020-06-04 Technion Research & Development Foundation Limited Agents which inhibit gads dimerization and methods of use thereof
US11660270B2 (en) 2017-07-20 2023-05-30 Indiana University Research And Technology Corporation Nanoparticle compositions
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combined treatment for cancer
IL253984A0 (en) 2017-08-14 2017-09-28 Yeda Res & Dev Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
IL274979B2 (en) 2017-11-29 2024-07-01 Univ Ramot Methods for the prevention and treatment of neurogenic seizures
EP3785279A4 (en) 2018-05-31 2022-07-27 Immunity Pharma Ltd. COMPOSITIONS AND METHODS OF USE THEREOF IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
US12134638B2 (en) 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Bistable type ii opsins and uses thereof
IL266728B (en) 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
US20220267409A1 (en) 2019-07-11 2022-08-25 Kahr Medical Ltd. Heterodimers and methods of use thereof
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
IL270800A (en) 2019-11-20 2021-05-31 Yeda Res & Dev A method for treating Alzheimer's disease
CN115335532A (zh) 2020-02-09 2022-11-11 Nlc制药有限公司 Sars-cov-2快速检测测试
WO2021176457A1 (en) 2020-03-05 2021-09-10 Ariel Scientific Innovations Ltd. Anti-hemorrhaging compositions
US20230127559A1 (en) 2020-03-16 2023-04-27 Yeda Research And Development Co. Ltd. Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
IL276627A (en) 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
WO2022064494A2 (en) 2020-09-23 2022-03-31 Yeda Research And Development Co. Ltd. Methods and compositions for treating coronaviral infections
CN116635056A (zh) 2020-10-07 2023-08-22 波塔力克斯有限公司 长效脱氧核糖核酸酶
EP4240423A1 (en) 2020-11-03 2023-09-13 Protalix Ltd. Modified uricase and uses thereof
EP4294428A1 (en) 2021-02-18 2023-12-27 Yeda Research and Development Co. Ltd Method of generating vaccines
IL283563A (en) 2021-05-30 2022-12-01 Yeda Res & Dev Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases
WO2023031934A1 (en) 2021-09-02 2023-03-09 Yeda Research And Development Co. Ltd. Agents that target the glycine arginine-rich domain of nucleolin and uses thereof
WO2024038462A1 (en) 2022-08-17 2024-02-22 Yeda Research And Development Co. Ltd. Novel bacteria-based delivery system for tace (adam17) selective biological inhibitor
WO2024241314A1 (en) 2023-05-22 2024-11-28 Neomanna Ltd Black soldier fly protein extracts

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4423037A (en) 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US4427827A (en) 1982-10-20 1984-01-24 Usv Pharmaceutical Corporation Synthesis of hormone fragments
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
US4771124A (en) 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
CA2040264A1 (en) 1990-04-12 1991-10-13 Tatsuhiko Kanmera Parathyroid hormone antagonists
CA2087087C (en) 1992-01-22 2000-07-18 Burton H. Sage, Jr. Molecules for iontophoretic delivery
US5434246A (en) 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
CA2098639A1 (en) 1992-06-19 1993-12-20 K. Anne Kronis Bone stimulating, non-vasoactive parathyroid hormone variants
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
ES2179831T3 (es) 1992-09-29 2003-02-01 Inhale Therapeutic Syst Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
CA2126299C (en) 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
CO4410206A1 (es) 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
DE19508672A1 (de) * 1995-03-10 1996-09-12 Boehringer Mannheim Gmbh Neue cyclische Parathormonfragmente, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE69629758T2 (de) 1995-06-07 2004-06-03 Compaq Computer Corp., Houston Verfahren und Vorrichtung für die Überwachung des Datenflusses in einem fehlertoleranten Multiprozessorsystem
US5717062A (en) * 1995-06-07 1998-02-10 Beth Israel Hospital Association Cyclic analogs of PTH and PTHrP
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
DK0915911T3 (da) * 1996-08-02 2004-03-08 Ca Nat Research Council Analoger til parathyreoideahormon til behandling af osteoporose

Also Published As

Publication number Publication date
AU746461B2 (en) 2002-05-02
EP0986395A4 (en) 2004-12-01
AP9901686A0 (en) 1999-12-31
OA11216A (en) 2003-07-10
ZA984077B (en) 1998-11-24
UA62967C2 (en) 2004-01-15
HUP0003349A3 (en) 2001-12-28
CA2290443A1 (en) 1998-11-19
NO995568L (no) 1999-12-29
AU7386798A (en) 1998-12-08
BG103957A (bg) 2000-04-28
HUP0003349A2 (hu) 2001-01-29
US6472505B1 (en) 2002-10-29
WO1998051324A1 (en) 1998-11-19
KR100351213B1 (ko) 2002-09-05
JP2001517957A (ja) 2001-10-09
EP0986395A1 (en) 2000-03-22
NO995568D0 (no) 1999-11-12
EA199901025A1 (ru) 2000-06-26
BR9808786A (pt) 2000-07-11
CN1261281A (zh) 2000-07-26
PL336803A1 (en) 2000-07-17
US20020132973A1 (en) 2002-09-19
KR20010012568A (ko) 2001-02-15
SK151599A3 (en) 2000-09-12
IL132901A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
EA002819B1 (ru) Циклическое пептидное соединение и его применение, бициклопептидное соединение, пептидное соединение и его применение, фармацевтическая композиция
KR0161972B1 (ko) 크기가 감소된 lhrh 동족체
JP6815686B2 (ja) 免疫調節剤としての1,2,4−オキサジアゾールおよびチアジアゾール化合物
SG10202111127YA (en) Cyclic Peptide Compound Having Kras Inhibitory Action
WO2023214576A1 (ja) Hrasおよびnrasに対して選択的なkras阻害作用を有する環状化合物
RU2496788C2 (ru) Аналоги окситоцина
EP0315367B1 (en) Polypeptides
HU196227B (en) Process for producing new cyclic vasopressin antagonist peptides and pharmaceutics comprising the same
US5717062A (en) Cyclic analogs of PTH and PTHrP
HU213098B (en) Process for producing decapeptides antagonistic to hormone for releazing lutheinizing-hormone and pharmaceutical compositions containing them as active components
JPH06503090A (ja) ノナペプチドのボンベシン拮抗薬
JP3801867B2 (ja) 改善された溶解特性を有する新規のlhrhアンタゴニスト
JPH0249800A (ja) ポリペプチド化合物、その製法並びにボンベシン又はボンベシン様ペプチドが仲介する疾患又は医学的症状を治療する製薬的組成物
MX2011010968A (es) Peptidos de cadena corta como agonistas de los receptores de la hormona paratiroidea (pth).
SK12097A3 (en) Parathormone derivatives and parathormone correlated peptide, preparation method thereof and pharmaceutical composition containing them
NO854645L (no) Fremgangsmaate for fremstilling av basiske cykliske peptider.
IE902958A1 (en) Substance P antagonists
JPH08505611A (ja) 5位及び6位に修飾アミノアシル残基を有するlhrh拮抗薬
EP1539803B1 (en) Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity
US4760052A (en) 1,6-dicarba-vasopressin compounds
WO1989007451A1 (en) Reduced size lhrh analogs
CA2118588A1 (en) Neuromedin b receptor antagonists
CA2005420C (en) Competitive gonadoliberin antagonists
US4684621A (en) Methods of producing vasodilation or antioxytocic activity
MXPA99010562A (en) Peptide parathyroid hormone analogs

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU